Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, and Department of Medical Biotechnologies, University of Siena, Italy.
Clin Exp Rheumatol. 2021 Mar-Apr;39(2):231-241. doi: 10.55563/clinexprheumatol/7gzsxp. Epub 2021 Apr 9.
In 2020 many contributions have been produced on SLE. Our critical digest of the recent literature will be focused on genetic factors that contribute to the development of the disease, novel potential therapeutic targets (including IL-23, IL-17, interferons and JAKs), diagnostic and prognostic biomarkers, classification criteria, clinical manifestations and comorbidities. We will then present new treatment options (with a special focus on belimumab, anifrolumab, tacrolimus, voclosporin and EULAR/ERA-EDTA recommendations for the management of LN) and treat-to-target strategy. Lastly, we will concentrate on some of the aspects that influence patients' disease perception and quality of life.
2020 年，人们对系统性红斑狼疮（SLE）进行了许多研究。我们对近期文献的批判性综述将集中在导致疾病发展的遗传因素、新型潜在治疗靶点（包括 IL-23、IL-17、干扰素和 JAKs）、诊断和预后生物标志物、分类标准、临床表现和合并症上。然后，我们将介绍新的治疗选择（特别关注贝利尤单抗、阿尼鲁单抗、他克莫司、 voclosporin 和 EULAR/ERA-EDTA 对 LN 管理的建议）和达标治疗策略。最后，我们将集中讨论一些影响患者疾病认知和生活质量的方面。
